Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Weidmann, E.
Right arrow Articles by Mitrou, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weidmann, E.
Right arrow Articles by Mitrou, P. S.
Related Collections
Right arrow 2004 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:369-374, 2004
© 2004 European Society for Medical Oncology

Diagnosis and actual therapy strategies in peripheral T-cell lymphomas: summary of an international meeting

E. Weidmann1,*, M. Gramatzki2, M. Wilhelm3 and P. S. Mitrou1

1 Department of Medicine III, JW-Goethe University, Frankfurt/Main; 2 Department of Medicine III, University of Erlangen Nürnberg, Erlangen; 3 Medizinische Poliklinik, University of Würzburg, Würzburg, Germany

Received 13 May 2003; revised 31 July 2003; accepted 13 August 2003

Key words: histopathology, immunology, molecular biology and genetics, peripheral T-cell lymphoma, treatment

The first 150 words of the full text of this article appear below.

Introduction

Peripheral T-cell lymphomas (PTCL) according to the REAL classification (mature T-cell lymphomas of the WHO classification) comprise no more than 10% of all non-Hodgkin’s lymphomas in the Western hemisphere [1]. Until now, uncertainties regarding many features of these rather heterogeneous diseases have prevented progress in developing effective therapies. PTCL has often been assessed as part of clinical studies focusing on the more common B-cell lymphomas and, consequently, our understanding of how to treat this group of lymphomas remains less clear than for B-cell lymphomas.

With the exception of a few subgroups, the prognosis of PTCL is poor, partly due to a limited understanding of their pathophysiological features. There is considerable variability in clinical presentation, which may greatly prolong the time taken to reach an accurate diagnosis in an individual patient. Additionally, treatment standards in PTCL have not yet been established [2].

Challenged by this variety of . . . [Full Text of this Article]

Immunology and histological classification

Cytogenetics and molecular genetics

Treatment of primary cutaneous and disseminated T-cell lymphomas

Antibody treatment of T-cell malignancies

Introduction of current treatment studies in peripheral T-cell lymphomas

Conclusions

Acknowledgements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 haematolHome page
H.-T. Arkenau, G. Chong, D. Cunningham, D. Watkins, B. Sirohi, I. Chau, A. Wotherspoon, A. Norman, A. Horwich, and E. Matutes
Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience
Haematologica, February 1, 2007; 92(2): 271 - 272.
[Abstract] [Full Text] [PDF]